iC9.B7-H3 CAR-T (Massachusetts General Hospital)

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameiC9.B7-H3 CAR-T (Massachusetts General Hospital)

Drug Alias NameiCas9.B7-H3 CAR T cellsiCas9.B7-H3 CAR T cells (Massachusetts General Hospital)iC9.B7-H3 CAR-T

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCaspase-9 modulatorsAnti-CD276

TargetsCaspase-9CD276 antigen

Therapy Area/IndicationsUveal melanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMassachusetts General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesMassachusetts General Hospital

Inactive CompaniesN/A

Active IndicationsUveal melanoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A